TapImmune, Inc. (TPIM.OB) Lead Product Receives Medical Attention
QualityStocks (June 3rd, 2008) Writes:
TapImmune, Inc. (OTCBB: TPIM) announced that their TAP incorporated vaccine for the treatment of cancer was recently reviewed by a third party research article in the Journal of Investigative Dermatology, which confirmed that the company’s vaccine should be considered as a therapy for cancer.
The article, entitled, “Restoration of the Expression of Transporters Associate with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity,” was published in advance online on April 3, 2008. TapImmune is a biotechnology company that specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, and the company’s stock rose 37.10% in Monday’s trading.
The company’s promising TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, which stands for Transporters with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without
...Antigen Processing, biotech, Biotechnology Company, Cancer Cells, Cancer Markers, Cancer Therapy, Cancerous Cells, Clinical Evaluation, Current Market News, Immunotherapeutics, Infectious Diseases, Initial Description, Journal Of Investigative Dermatology, Malignant Melanoma, Medical Attention, Otcbb, OTCBB Markets, Research Article, Rogue Cells, S Trading, Small & Micro Cap, Stocks to Watch, Treatment Of Cancer, Tumor Recognition, Viral Antigens


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
